ArticleJournal of Korean medical science2023

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023.

Jinyoung Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.